Ree Nar Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ree Nar Yoo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jina Lee
Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
7 shared publications - Gahee Kim
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Ho Joon Im
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Hyejin So
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications - Hyery Kim
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
2 shared publications - Jung Hwa Kim
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Infection & Chemotherapy
- Vol. 58
Gut Microbiome Profiles of Pediatric HSCT Recipients and Donors in Relation to Acute Graft-versus-Host Disease: A Pilot Study
Seo E, et al. Infect Chemother. 2026 ;58:e54. https://doi.org/10.3947/ic.2026.0038
- 1 January 2026
- Published by XMLink in Infection & Chemotherapy
- Vol. 58
Open AccessGut Microbiome Profiles of Pediatric HSCT Recipients and Donors in Relation to Acute Graft-versus-Host Disease: A Pilot Study
Seo E, et al. Infect Chemother. 2026 ;58:e54. https://doi.org/10.3947/ic.2026.0038
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (9) , e87
Dynamics of Varicella Zoster Virus-Specific Immune Reconstitution and Impact of Varicella Vaccination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients
Kim G, et al. J Korean Med Sci. 2026 Mar;41:e87. https://doi.org/10.3346/jkms.2026.41.e87
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (9) , e87
Open AccessDynamics of Varicella Zoster Virus-Specific Immune Reconstitution and Impact of Varicella Vaccination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients
Kim G, et al. J Korean Med Sci. 2026 Mar;41:e87. https://doi.org/10.3346/jkms.2026.41.e87
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (33) , e252
Clinical Manifestation of Ralstonia mannitolilytica Infection in Pediatric Patients and Epidemiological Investigation of Outbreaks
Kim G, et al. J Korean Med Sci. 2023 Aug;38(33):e252. https://doi.org/10.3346/jkms.2023.38.e252
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (33) , e252
Open AccessClinical Manifestation of Ralstonia mannitolilytica Infection in Pediatric Patients and Epidemiological Investigation of Outbreaks
Kim G, et al. J Korean Med Sci. 2023 Aug;38(33):e252. https://doi.org/10.3346/jkms.2023.38.e252
- Open Access
- 1 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0247714
Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
Optimal vancomycin exposure is important to minimize treatment failure of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. We aimed to analyze the impact of initial vancomycin pharmacokinetic/pharmacodynamic (PK/PD) parameters, including the initial vancomycin C trough and the area under the curve (AUC)/minimal inhibitory concentration (MIC) on the outcomes of pediatric MRSA bacteremia. The study population consisted of hospitalized children aged between 2 months and 18 years with MRSA bacteremia, in whom C trough was measured at least one time within the time period of January 2010 to March 2018. Demographic profiles, underlying diseases, and clinical/microbiological outcomes were abstracted retrospectively. During the study period, 73 cases of MRSA bacteremia occurred in children with a median age of 12.4 months. Severe clinical outcomes leading to intensive care unit stay and/or use of mechanical ventilation occurred in 47.5% (35/73); all-cause 30-day mortality was 9.7% (7/72). The median dosage of vancomycin was 40.0 mg/kg/day. There was a weak linear relationship between C trough and the corresponding AUC/MIC (r = 0.235). ROC curves for achieving an AUC/MIC of 300 suggested that the initial C trough at 10 μg/mL could be used as a cut-off value with a sensitivity of 90.5% and a specificity of 44%. Although persistent bacteremia at 48–72 hours after vancomycin administration was observed more frequently when the initial C trough was < 10 μg/mL and initial AUC/MIC was < 300, initial AUC/MIC < 300 was the only risk factor associated with persistent bacteremia at 48–72 hours (adjusted OR 3.05; 95% CI, 1.07–8.68). Initial C trough and AUC/MIC were not associated with 30-day mortality. Although there was a weak relationship between C trough and AUC/MIC, initial AUC/MIC < 300 could be used as a predictor of persistent MRSA bacteremia at 48–72 hours. Further prospective data on optimal vancomycin dosing are necessary to improve clinical and microbiological outcomes in pediatric MRSA bacteremia.
- 1 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0247714
Open AccessImpact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
Optimal vancomycin exposure is important to minimize treatment failure of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. We aimed to analyze the impact of initial vancomycin pharmacokinetic/pharmacodynamic (PK/PD) parameters, including the initial vancomycin C trough and the area under the curve (AUC)/minimal inhibitory concentration (MIC) on the outcomes of pediatric MRSA bacteremia. The study population consisted of hospitalized children aged between 2 months and 18 years with MRSA bacteremia, in whom C trough was measured at least one time within the time period of January 2010 to March 2018. Demographic profiles, underlying diseases, and clinical/microbiological outcomes were abstracted retrospectively. During the study period, 73 cases of MRSA bacteremia occurred in children with a median age of 12.4 months. Severe clinical outcomes leading to intensive care unit stay and/or use of mechanical ventilation occurred in 47.5% (35/73); all-cause 30-day mortality was 9.7% (7/72). The median dosage of vancomycin was 40.0 mg/kg/day. There was a weak linear relationship between C trough and the corresponding AUC/MIC (r = 0.235). ROC curves for achieving an AUC/MIC of 300 suggested that the initial C trough at 10 μg/mL could be used as a cut-off value with a sensitivity of 90.5% and a specificity of 44%. Although persistent bacteremia at 48–72 hours after vancomycin administration was observed more frequently when the initial C trough was < 10 μg/mL and initial AUC/MIC was < 300, initial AUC/MIC < 300 was the only risk factor associated with persistent bacteremia at 48–72 hours (adjusted OR 3.05; 95% CI, 1.07–8.68). Initial C trough and AUC/MIC were not associated with 30-day mortality. Although there was a weak relationship between C trough and AUC/MIC, initial AUC/MIC < 300 could be used as a predictor of persistent MRSA bacteremia at 48–72 hours. Further prospective data on optimal vancomycin dosing are necessary to improve clinical and microbiological outcomes in pediatric MRSA bacteremia.
- Open Access
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (2) , 82-91
The Impact of Antibiotic Burden on the Selective Resistance of Gram Negative Bacteria in Children
박세라, et al. Pediatr Infect Vaccine. 2021 Aug;28(2):82-91. https://doi.org/10.14776/piv.2021.28.e11
- 1 January 2021
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 28 (2) , 82-91
Open AccessThe Impact of Antibiotic Burden on the Selective Resistance of Gram Negative Bacteria in Children
박세라, et al. Pediatr Infect Vaccine. 2021 Aug;28(2):82-91. https://doi.org/10.14776/piv.2021.28.e11
- Open Access
- 1 January 2019
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 26 (1) , 1-10
Antibiotics Susceptability ofStreptococcus pneumoniaeIsolated from Single Tertiary Childrens' Hospital Since 2014 and Choice of Appropriate Empirical Antibiotics
Jung J, et al. Pediatr Infect Vaccine. 2019 Apr;26(1):1-10. https://doi.org/10.14776/piv.2019.26.e1
- 1 January 2019
- Published by XMLink in Pediatric Infection & Vaccine
- Vol. 26 (1) , 1-10
Open AccessAntibiotics Susceptability ofStreptococcus pneumoniaeIsolated from Single Tertiary Childrens' Hospital Since 2014 and Choice of Appropriate Empirical Antibiotics
Jung J, et al. Pediatr Infect Vaccine. 2019 Apr;26(1):1-10. https://doi.org/10.14776/piv.2019.26.e1
- Open Access
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (1) , 22-28
Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-ResistantStaphylococcus aureusBacteremia in Children
Yoo RN, et al. J Korean Med Sci. 2017 Jan;32(1):22-28. https://doi.org/10.3346/jkms.2017.32.1.22
- 1 January 2017
- Published by XMLink in Journal of Korean Medical Science
- Vol. 32 (1) , 22-28
Open AccessImpact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-ResistantStaphylococcus aureusBacteremia in Children
Yoo RN, et al. J Korean Med Sci. 2017 Jan;32(1):22-28. https://doi.org/10.3346/jkms.2017.32.1.22